GB2125292A — Stable aqueous formulations of vinca alkaloids
Assigned to Eli Lilly and Co · Expires 1984-03-07 · 42y expired
What this patent protects
This invention provides stable, sterile, ready-to-use formulations of oncolytic vinca dimers comprising an aqueous solution of the vinca dimer (e.g. vincristine, vinblastine, vindesine, 4 min -deoxy-1-formyl-leurosidine or leuraformine) as a pharmaceutically acceptable water-solu…
USPTO Abstract
This invention provides stable, sterile, ready-to-use formulations of oncolytic vinca dimers comprising an aqueous solution of the vinca dimer (e.g. vincristine, vinblastine, vindesine, 4 min -deoxy-1-formyl-leurosidine or leuraformine) as a pharmaceutically acceptable water-soluble salt, an acetate buffer maintaining the pH between 3.0 and 5.0, a polyol (e.g. lactose, mannitol, sorbitol), and a preservative which is preferably methyl paraben and/or propyl paraben.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.